Masimo (NASDAQ:MASI) Given New $205.00 Price Target at Wells Fargo & Company

Masimo (NASDAQ:MASI) had its price target hoisted by investment analysts at Wells Fargo & Company from $193.00 to $205.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 10.10% from the stock’s previous close.

A number of other brokerages have also issued reports on MASI. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Piper Sandler lifted their price objective on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Masimo has an average rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Down 2.2 %

NASDAQ MASI opened at $186.20 on Wednesday. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a fifty day moving average of $172.95 and a two-hundred day moving average of $153.10. The firm has a market capitalization of $9.97 billion, a price-to-earnings ratio of 128.41 and a beta of 1.02. Masimo has a 52 week low of $101.61 and a 52 week high of $192.62.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. On average, analysts predict that Masimo will post 4.1 earnings per share for the current year.

Hedge Funds Weigh In On Masimo

Large investors have recently added to or reduced their stakes in the company. ING Groep NV grew its stake in shares of Masimo by 143.3% during the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock worth $32,119,000 after acquiring an additional 141,900 shares during the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after acquiring an additional 262,370 shares during the last quarter. National Bank of Canada FI grew its stake in shares of Masimo by 195.6% during the third quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider’s stock worth $17,666,000 after acquiring an additional 87,675 shares during the last quarter. Lecap Asset Management Ltd. purchased a new stake in shares of Masimo during the fourth quarter worth about $1,607,000. Finally, Nisa Investment Advisors LLC grew its stake in shares of Masimo by 16,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider’s stock worth $835,000 after acquiring an additional 5,022 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.